Phosphate metabolism is an evolving area of basic and clinical research. In the past 15
years, knowledge on disturbances of phosphate homoeostasis has expanded, as has the …

Abstract X‐linked hypophosphatemia (XLH), the most common form of hereditary
hypophosphatemia, is caused by disrupting variants in the PHEX gene, located on the X …

Hypophosphatemic rickets typically presents in infancy or early childhood with skeletal
deformities and growth plate abnormalities. The most common causes are genetic (such as …

X-linked hypophosphatemia (XLH) is a rare, hereditary, progressive musculoskeletal
disease that often causes pain and short stature, as well as decreased physical function …

Abstract Fibroblast growth factor 23 (FGF23), one of the endocrine fibroblast growth factors,
is a principal regulator in the maintenance of serum phosphorus concentration. Binding to its …

The endocrinologist Fuller Albright has been credited with the first description of
hypophosphatemic rickets (HR) that failed to respond to high doses of vitamin D. The …

Objectives To report the impact of burosumab on patient-reported outcomes (PROs) and
ambulatory function in adults with X-linked hypophosphataemia (XLH) through 96 weeks …

Burosumab (KRN23) is an FGF23 neutralizing antibody that has been the subject of several
recent clinical trials principally focused on the treatment of hypophosphatemic rickets in …

X-linked Hypophosphatemia (XLH) is caused by loss of function mutations in the PHEX
gene. Given the recent availability of a new therapy for XLH, a retrospective analysis of the …

Fibroblast growth factor‐23 (FGF23) controls the homeostasis of both phosphate and vitamin
D. Bone-derived FGF23 can suppress the transcription of 1α‐hydroxylase (1α (OH) ase) to …